Uncategorized

Azura Ophthalmics Announces Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction

by Business Wire • 2022/11/17 • 0 Comments

TEL AVIV, Israel & MELBOURNE, Australia--(BUSINESS WIRE)--Azura Ophthalmics Announces Positive Phase 2b Results from Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction

← NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin Returns to the QVC® Network With DERMAdoctor’s Eczema Balm

VIDEO: Gene therapy shows growing promise in treatment of retinal diseases →

Post navigation